Tag Archives: CDC

U.S. administers 168.6 million doses of COVID-19 vaccines: CDC

(Reuters) – The United States has administered 168,592,075 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 219,194,215 doses, the U.S. Centers for Disease Control and Prevention said.

The tally is for Moderna, Pfizer/BioNTech, and Johnson & Johnson’s vaccines as of 6:00 a.m. ET on Tuesday, the agency said.

According to the tally posted on April 5, the agency had administered 167,187,795 doses of the vaccines, and distributed 207,891,395 doses.

The agency said 108,301,234 people had received at least one dose while 63,016,976 people are fully vaccinated as of Tuesday.

A total of 7,748,620 vaccine doses have been administered in long-term care facilities, the agency said.

(Reporting by Manojna Maddipatla in Bengaluru)

U.S. says 165 million doses of COVID-19 vaccine been administered so far

(Reuters) – The United States has administered more than 165 million doses of COVID-19 vaccines in the country as of Sunday morning and distributed nearly 208 million, the U.S. Centers for Disease Control and Prevention (CDC) said on Sunday.

That is up from the 161,688,422 vaccine doses the CDC said had gone into arms by Saturday out of 207,866,645 doses delivered.

The agency said 106,214,924 people had received at least one vaccine dose, while 61,416,536 people have been fully vaccinated as of Sunday.

The CDC tally includes two-dose vaccines from Moderna Inc and Pfizer/BioNTech,, as well Johnson & Johnson’s one-shot vaccine as of 6:00 a.m. ET on Sunday.

A total of 7,742,126 vaccine doses have been administered in long-term care facilities, the agency said.

(Reporting by Aishwarya Nair in Bengaluru; Editing by Bill Berkrot)

CDC discourages Americans from travel despite ‘low risk’ to vaccinated people

By David Shepardson and Jeff Mason

WASHINGTON (Reuters) – The U.S. Centers for Disease Control and Prevention on Friday said people who are fully vaccinated against COVID-19 can safely travel at “low risk” but still discouraged Americans from doing so because of high coronavirus cases nationwide.

The CDC’s shift in guidance should be a shot in the arm for the travel industry, which is still struggling from the dip in passengers since the onset of the pandemic in 2020.

But CDC Director Rochelle Walensky told reporters that, despite the new guidance for vaccinated people, now was not a good time to take a trip.

“We know that right now we have a surging number of cases. I would advocate against general travel overall,” she said. “We are not recommending travel at this time, especially for unvaccinated individuals.”

The CDC had held off changing its travel guidance even as vaccinations increased, irking the travel industry.

Its new guidance on Friday seemed to be an attempt to thread a needle of acknowledging that vaccines made travel significantly safer while seeking to thwart a big increase until more people have had their shots.

The new guidance greenlights vaccinated grandparents getting on airplanes to see grandchildren, for example, and says COVID-19 testing and quarantining are not necessary before or after travel as long as take precautions such as wearing masks and maintaining social distance.

A group representing major U.S. airlines including American Airlines, Delta Air lines, United Airlines Southwest Airlines and other trade groups had urged the CDC on March 22 to immediately update its guidance to say “vaccinated individuals can travel safely.” Air travel still remains down 43% from pre-COVID levels and business and international travel remain even harder hit.

Roger Dow, chief executive of the U.S. Travel Association, said the “new travel guidance is a major step in the right direction that is supported by the science and will take the brakes off the industry that has been hardest hit by the fallout of COVID by far.”

The administration is not lifting restrictions that bar most-non U.S. citizens from the United States who have recently been in China, Brazil, South Africa and most of Europe. It is also keeping requirements that nearly all international U.S. air visitors getting a negative COVID-19 test before traveling to the United States.

A U.S. official briefed on the matter said the Biden administration is beginning to have conversations about how and when it might eventually lift those travel restrictions but no change is imminent. The United States also still maintains restrictions at the Canadian and Mexican borders that bar non-essential visitors.

The CDC’s new guidance says fully vaccinated people do not need COVID-19 tests before international travel unless it is required by the international destination and vaccinated people returning from foreign travel do not need to self-quarantine after returning to the United States, unless required by state or local authorities.

The CDC had repeatedly declined in recent weeks to change the guidance and repeated it was still discouraging all non-essential travel because of a concern about new variants.

Many Americans have not been heeding the CDC’s advice.

The Transportation Security Administration screened 1.56 million people at U.S. airports on Thursday, just below Sunday’s 1.57 million, which was the highest daily total since March 2020. The last time the number of airport passengers screened was below 1 million was March 10.

The Biden administration has taken steps to reduce international travel and mandated masks in nearly all forms of public transit. The administration is not eliminating any mask rules.

The administration is sticking by its goal that all adults will be eligible for vaccines in the coming weeks. Infectious disease expert Dr. Anthony Fauci told reporters that studies showed children would be able to be vaccinated, too.

“There are studies under way in children that go from six months to 11 years. And by the end of this year we should have enough information to be able to safely vaccinate children of virtually any age,” he said.

(Reporting by David Shepardson and Jeff Mason; Additional reporting by Doina Chiacu; Editing by Chizu Nomiyama and Marguerita Choy)

COVID-19 third leading cause of U.S. deaths in 2020 after heart disease, cancer: U.S. report

By Vishwadha Chander

(Reuters) – COVID-19 was the primary or contributing cause of 377,883 deaths in the United States last year, with a particularly high toll among the elderly, according to a government report released on Wednesday.

The COVID-19 mortality rate made it the third leading cause of death in the United States in 2020 after heart disease and cancer, the U.S. Centers for Disease Control and Prevention (CDC) analysis found.

The CDC said that the overall U.S. mortality rate increased for the first time since 2017, by nearly 16%, to 3,358,814 deaths. The jump was driven by COVID-19, which accounted for an increase of 11.3%.

The overall death rate was lowest among children aged 5 to 14 years, and highest among people over age 85, the report found. A total of 134 children aged 14 and under died from COVID-19 in 2020, while 120,648 people aged 85 and older died from the disease. People 75-84 years old accounted for 104,212 deaths.

The COVID-19 death rate was highest among Hispanics, followed by Black non-Hispanics, the CDC’s analysis found. A total of 68,469 Hispanics died from COVID-19 and 59,871 non-Hispanic Black people died. It said 228,328 White non-Hispanics died.

The CDC report is based on death certificate data between January and December 2020.

Provisional estimates from the CDC, published last month, showed that life expectancy in the U.S. fell by a year in the first half of 2020 – the biggest decline since World War 2 – and stood at the lowest levels since 2006.

The CDC’s current analysis is based on provisional death estimates, but they provide an early indication of shifts in mortality trends, the agency said.

The CDC pointed out that limited availability of testing for the coronavirus at the beginning of the pandemic might have resulted in an underestimation of COVID-19–associated deaths.

(Reporting by Reporting by Vishwadha Chander and Caroline Humer; Editing by Bill Berkrot)

Immune response may be linked to AstraZeneca vaccine clot issue; death risk rising among young adults in Brazil

By Nancy Lapid

(Reuters) -The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Immune response may explain rare clots after AstraZeneca vaccine

Researchers may have found an explanation for the rare but serious blood clots reported among some people who received AstraZeneca’s COVID-19 vaccine. They believe the phenomenon is similar to one that rarely occurs with a blood thinning drug called heparin, called heparin-induced thrombocytopenia (HIT). In HIT, the drug triggers the immune system to produce antibodies that activate platelets, which cause blood to clot. Drugs other than heparin can cause clotting disorders that strongly resemble HIT, and researchers suspect that in rare cases, the AstraZeneca vaccine may be another such trigger. Four previously healthy individuals who got the AstraZeneca shot and developed life-threatening clots had the same kind of antibodies that activate platelets and initiate clotting in HIT, the researchers reported on Monday in a paper posted on Research Square ahead of peer review. Twenty individuals who received the vaccine but did not develop clots did not have these antibodies. An editorial comment posted with the study noted that drug-induced thrombocytopenia is treatable if identified promptly. Millions of people have received the vaccine without issues and European regulators and the World Health Organization say the benefits of the AstraZeneca shot outweigh its risks.

COVID-19 death risk rising for young adults in Brazil

Southern Brazil is seeing a sudden rise in COVID-19 deaths among young and middle-aged adults after the identification there of a concerning virus variant known as P.1, researchers said. They analyzed data from Parana – the largest state in southern Brazil – on 553,518 cases diagnosed from September 2020 through March 17, 2021. In all age groups, the proportion of patients who died either held steady or declined between September and January. Starting in February, however, fatality rates rose for almost all groups over age 20, according to a report posted on Friday on medRxiv ahead of peer review. From January to February, these rates tripled among patients aged 20 to 29, from 0.04% to 0.13%, and doubled among those aged 30 to 39, 40 to 49, and 50 to 59. “Individuals between 20 and 29 years of age whose diagnosis was made in February 2021 had an over 3-fold higher risk of death compared to those diagnosed in January 2021,” the researchers said. “Taken together, these preliminary findings suggest significant increases in case fatality rates in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil, and this should raise public health alarms.”

Pfizer, Moderna vaccines limit asymptomatic infections

Vaccines from Pfizer Inc and partner BioNTech SE and from Moderna Inc dramatically reduced the risk of infection by the new coronavirus within weeks after the first of two shots, according to data from a study of nearly 4,000 U.S. healthcare personnel and first responders in six states. Previous trials by the companies evaluated the vaccines’ efficacy in preventing illness from COVID-19, but would have missed infections that did not cause symptoms. In the new study, conducted from mid-December to mid-March, nearly 75% of participants had received at least one dose of vaccine, and everyone had weekly coronavirus testing for 13 consecutive weeks in order to pick up asymptomatic infections. According to a report published on Monday by the U.S. Centers for Disease Control and Prevention (CDC), the risk of infection fell by 80% two weeks or more after the first of two shots and by 90% by two weeks after the second shot. “The authorized mRNA COVID-19 vaccines provided early, substantial real-world protection against infection for our nation’s healthcare personnel, first responders, and other frontline essential workers,” CDC Director Rochelle Walensky said in a statement.

Pandemic has cut parents’ access to hospitalized children

Pediatricians have long endorsed the idea that babies and children in hospitals should not be separated from their families – a practice that in many facilities was restricted or discontinued to limit COVID-19 infections, according to new research. From mid-May through early July, researchers collected survey responses from 96 pediatric care units in 22 countries in Europe, Asia, and North America. The results – mostly from intensive care units for newborns – showed that before the pandemic, 87% of units welcomed families and 92% encouraged skin-to-skin care, according to a report published in Journal of Perinatology. After the onset of the pandemic, more than 83% of the hospital units restricted family presence, with additional restrictions placed on parental participation in their infant’s care, said study coauthor Ita Litmanovitz of Meir Medical Center in Kfar Saba, Israel. Hospitals’ decisions to limit family access did not depend on their previous rules, the availability of single-family rooms, or the virus infection rate in the hospital’s geographical area. “Restrictions during the pandemic increased separation between the infant and family,” the researchers found. These restrictions, Litmanovitz added, “go against psychological and neuroscientific evidence in support of unrestricted parental presence and ability to care for their hospitalized infants.”

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

Pfizer, Moderna COVID-19 vaccines highly effective after first shot in real-world use, -U.S. study

By Ankur Banerjee and Vishwadha Chander

(Reuters) – COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced the risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world U.S. study released on Monday.

The risk of infection fell 90% by two weeks after the second shot, the study of just under 4,000 vaccinated U.S. healthcare personnel and first responders found.

The study by the U.S. Centers for Disease Control and Prevention (CDC) evaluated the vaccines’ ability to protect against infection, including infections that did not cause symptoms. Previous clinical trials by the companies evaluated their vaccine’s efficacy in preventing illness from COVID-19.

The findings from of the real-world use of these messenger RNA (mRNA) vaccines confirm the efficacy demonstrated in the large controlled clinical trials conducted before they received emergency use authorizations from the U.S. Food and Drug Administration.

The study looked at the effectiveness of the mRNA vaccines among 3,950 participants in six states over a 13-week period from Dec. 14, 2020 to March 13, 2021.

“The authorized mRNA COVID-19 vaccines provided early, substantial real-world protection against infection for our nation’s healthcare personnel, first responders, and other frontline essential workers,” CDC Director Rochelle Walensky said in a statement.

The new mRNA technology is a synthetic form of a natural chemical messenger being used to instruct cells to make proteins that mirror part of the novel coronavirus. That teaches the immune system to recognize and attack the actual virus.

The CDC study comes weeks after real-world data from Israel suggested that the Pfizer/BioNTech vaccine was 94% effective in preventing asymptomatic infections.

Some countries, including Britain and Canada, are allowing extended gaps between doses that differ from how the vaccines were tested in clinical trials in order to alleviate supply constraints. In the trials, there was a three-week gap between Pfizer shots and four weeks for the Moderna vaccine.

In Britain, authorities said in January that data supported its decision to move to 12 weeks between the first and second Pfizer/BioNtech shots. Pfizer and its German partner have warned that they had no evidence to prove that.

(Reporting by Ankur Banerjee and Vishwadha Chander in Bengaluru; Editing by Peter Henderson and Bill Berkrot)

U.S. administers nearly 137 million doses of COVID-19 vaccines: CDC

(Reuters) – The United States has administered 136,684,688 doses of COVID-19 vaccines and distributed 177,501,775 doses in the country as of Friday morning, the U.S. Centers for Disease Control and Prevention said.

The tally is for Moderna, Pfizer/BioNTech, and Johnson & Johnson’s vaccines as of 6:00 a.m. ET on Friday, the agency said.

According to the tally posted on March 25, the agency had administered 133,305,295 doses of the vaccines, and distributed 173,525,335 doses.

The agency said 89,559,225 people have received at least one dose, while 48,695,172 people were fully vaccinated as of Friday.

A total of 7,699,428 vaccine doses have been administered in long-term care facilities, the agency said.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

More under-30 Americans report anxiety, depression during pandemic – CDC

By Vishwadha Chander

(Reuters) – More young adults in the United States reported feeling anxious or depressed during the past six months of the COVID-19 pandemic, and fewer people reported getting the help they needed, according to a U.S. government study released on Friday.

The percentage of adults under age 30 with recent symptoms of an anxiety or a depressive disorder rose significantly about five months after the U.S. imposed COVID-19 related lockdowns, and reported rising deaths from the fast-spreading virus.

Between August 2020 and February 2021, this number went up to 41.5% from 36.4%, as did the percentage of such people reporting that they needed, but did not receive, mental health counseling.

The study suggests that the rise in anxiety or depressive disorder symptoms reported correspond with the weekly number of reported COVID-19 cases.

The findings are based on a Household Pulse Survey conducted by the U.S. Centers for Disease Control and Prevention (CDC) and the Census Bureau to monitor changes in mental health status and access to care during the pandemic.

“Trends in mental health can be used to evaluate the impact of strategies addressing adult mental health status and care during the pandemic,” the authors of the study wrote in the CDC’s Morbidity and Mortality Weekly Report released on Friday.

The study also found those with less than a high school education were more at risk, though it did not provide an explanation for it.

Even with more vaccines gaining authorization beginning late 2020, the effects of the pandemic on mental health continued into 2021.

During Jan. 20, 2021 through Feb. 1, 2021, about two in five adults aged over 18 years experienced recent symptoms of an anxiety or a depressive disorder, the survey found.

Demand for mental health and meditation apps, and investments in tech startups building these apps have also risen during this period.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Caroline Humer and Shailesh Kuber)

New U.S. COVID-19 cases show weekly uptick for first time since January

(Reuters) – New cases of COVID-19 in the United States rose 5% to more than 394,000 last week, the first increase after declining for nine straight weeks, according to a Reuters analysis of state, county and CDC data.

Thirty out of 50 states reported more new infections in the week ended March 21 compared with the previous seven days, up from 19 states in the prior week, according to the Reuters analysis.

Nationally, the weekly number of new cases had been on a downward trend since January, though health authorities have warned that infections could surge again if Americans relaxed social distancing restrictions too quickly. More infectious variants have also spread across the country.

“I am worried that if we don’t take the right actions now we will have another avoidable surge just as we are seeing in Europe right now and just as we are so aggressively scaling up vaccinations,” said Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, on Monday.

The Northeast logged some of the highest rates of infection per capita, led by New Jersey, New York and Rhode Island.

Deaths from COVID fell 15% to 7,793 last week, or about 1,100 per day, according to the Reuters analysis. Health officials hope the country’s vaccination effort can prevent a rise in deaths even if cases surge again.

For a fourth week, daily average vaccinations set a record, with 2.5 million shots given per day last week. As of Sunday, 25% of the U.S. population has received at least one dose of a vaccine, up from 21% a week ago, according to the Centers for Disease Control and Prevention. About 13% has received two doses, up from 11%.

The average number of COVID-19 patients in U.S. hospitals fell 6% to 36,000, the lowest since October, according to a Reuters tally.

Hospitalizations have fallen for 10 weeks nationally, but they are rising in 18 states, up from four states the previous week.

(Graphic by Chris Canipe, writing by Lisa Shumaker, editing by Tiffany Wu)

U.S. administers 118.3 million doses of COVID-19 vaccines: CDC

(Reuters) – The United States has administered 118,313,818 doses of COVID-19 vaccines in the country as of Friday morning and distributed 154,199,235 doses, the U.S. Centers for Disease Control and Prevention said.

The tally is for Moderna, Pfizer/BioNTech, and Johnson & Johnson’s vaccines as of 6:00 a.m. ET on Friday, the agency said.

According to the tally posted on March 18, the agency had administered 115,730,008 doses of the vaccines, and distributed 151,108,445 doses.

The agency said 77,230,061 people had received at least one dose while 41,934,629 people are fully vaccinated as of Friday.

A total of 7,630,706 vaccine doses have been administered in long-term care facilities, the agency said.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)